1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,900 | 12,980 | 18:28 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:30 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 48 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 30.06. | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 82 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04. | Devyser Q1 2025 slides reveal mixed results with 8% growth, EBIT challenges | 1 | Investing.com | ||
| 29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 335 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 177 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 209 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 309 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 183 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 700 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| 30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 137 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen | |
| 23.07.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2024 | 177 | GlobeNewswire (Europe) | "Devyser continued to report high sales growth in the second quarter. Organic growth compared with the same quarter of last year amounted to 41 percent in SEK. We won several large tenders during the... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 77,39 | +0,82 % | Medtronic Begins U.S. Trial Of Onyx LES For Peripheral Arterial Hemorrhage | DUBLIN (dpa-AFX) - Medtronic (MDT) has announced the enrollment of the first patient in its PELE (PEripheral Onyx Liquid Embolic) clinical trial, which will evaluate the safety and efficacy... ► Artikel lesen | |
| HCA HEALTHCARE | 304,30 | -2,41 % | 4iG Plc.: On the decision of the HCA regarding the transaction aimed at acquiring the Hungarian satellite customer base of Direct One | ||
| LANTHEUS | 60,76 | -0,78 % | Lantheus Holdings, Inc.: Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D | BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), today announced the successful completion of its previously disclosed acquisition... ► Artikel lesen | |
| AMEDISYS | 82,00 | 0,00 % | Amedisys Q1 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Amedisys (AMED) announced earnings for its first quarter that increased from the same period last year and beat the Street estimates.The company's bottom line totaled... ► Artikel lesen | |
| ENVISTA | 16,400 | -0,61 % | Envista Holdings Corp - 8-K, Current Report | ||
| CAREDX | 10,690 | -1,93 % | CareDx rebounds as draft LCD suggests no change in coverage | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Third Quarter 2025 Results | Reports 23 Percent Increase in ARR to $20.4 Million and 43 Net New Platform Deployments, Positive Net Income and Record Adjusted EBITDA and Cashflow
HENDERSON... ► Artikel lesen | |
| GT BIOPHARMA | 2,000 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals | Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results... ► Artikel lesen | |
| CARMAT | 0,281 | -6,49 % | CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
| CHEMOMETEC | 68,50 | -0,07 % | Chemometec A/S: Preliminary revenue figures for the 2024/25 financial year | ANNOUNCEMENT NO. 290 1 July 2025 Preliminary revenue figures for the 2024/25 financial year Based on the preliminary financial figures, ChemoMetec now expects revenue of around DKK 496 million... ► Artikel lesen | |
| ARRAIL GROUP | 0,248 | -3,12 % | ARRAIL GROUP (06639): CONNECTED TRANSACTION IN RELATION TO AMENDMENT TO THE LOAN AGREEMENT AND PLEDGE OF SHARES BY THE CONTROLLING SHAREHOLDER | ||
| POLAREAN IMAGING | 0,016 | 0,00 % | Polarean Imaging PLC - Promotion & sales representative agreement | ||
| PROMIMIC | 1,540 | -4,35 % | Curiteva & Promimic - Bonded by Innovation | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen | |
| FRESENIUS | 41,720 | +2,36 % | Aktie von Fresenius SE & Co. KGaA heute am Aktienmarkt kaum gefragt: Kurs fällt (41,21 €) | An der deutschen Börse notiert die Fresenius SE & Co. KGaA-Aktie derzeit ein wenig leichter. Die Aktie notiert zur Stunde bei 41,21 Euro. Der Anteilsschein von Fresenius+Co KgaA verzeichnet aktuell... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 45,680 | -0,26 % | Siemens Healthineers: Die Entscheidung rückt näher | Seit Ende Mai läuft die Siemens Healthineers-Aktie in einer engen Spanne seitwärts. Zuletzt wurde der Kurs durch ein stetes Für und Wider in diesem Käfig gehalten. Aber spätestens mit den näher rückenden... ► Artikel lesen |
DEVYSER DIAGNOSTICS AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 12,760 Euro und damit +9,62 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.